Skip to main content

Table 2 Diagnostic accuracy of various methylation biomarker panel

From: Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms

Biomarker

Area under the curve

P-value

Sensitivity (%)

Specificity (%)

ADAMTS1

0.73 (0.61–0.83)

0.001

60

86

BNC1

0.81 (0.70–0.90)

 < 0.001

66

97

CACNA1G

0.63 (0.50–0.74)

0.06

26

100

ADAMTS1/BNC1

0.80 (0.69–0.89)

 < 0.001

77

83

ADAMTS1/BNC1/CACNA1G

0.81 (0.70–0.90)

 < 0.001

83

80

BNC1/CACNA1G

0.84 (0.74–0.92)

 < 0.001

71

97

IPMN Lesion Size#

0.66 (0.53–0.77)

0.01

65

69

IPMN Lesion Size# and CA19-9

0.75(0.65–0.86)

0.03

66

82

CA19-9

0.61 (0.50–0.72)

0.06

34

88

IPMN Lesion Size#, CA19-9, & CACNA1G/BNC1

0.92 (0.86–0.98)

 < 0.001

94

88

  1. CA19-9 Carbohydrate antigen 19-9
  2. #Continuous variable